Disease Landscape and Forecast Insights

The ovarian cancer treatment algorithm is rapidly evolving. For decades, chemotherapy was the standard of care, but now, with the introduction of Roche/Genentech/Chugai’s Avastin and three PARP…

The poly ADP ribose polymerase (PARP) inhibitors, such as AstraZeneca’s Lynparza, GSK’s Zejula, and Clovis Oncology’s Rubraca, have revolutionized the therapeutic landscape of platinum-…

Market OutlookTargeted therapies are changing the treatment paradigm for ovarian cancer in the top 5 European markets (France, Germany, Italy, Spain, UK). Roche’s Avastin and small-molecule PARP…

Chemotherapy remains the standard of care for the treatment of ovarian cancer, but new classes of drugs such as angiogenesis inhibitors and, more recently, PARP inhibitors have entered the…

KEY BENEFITS AND USES Pinpoint current drug positioning and uptake in one snapshot to facilitate forecasting. Drill down into physicians’ treatment sequences and understand who the…

The premium-priced therapies used to treat ovarian cancer, such as Avastin (Roche/Genentech) and the PARP inhibitors Lynparza (AstraZeneca/Merck & Co), Rubraca (Clovis Oncology), and Zejula (…

The ovarian cancer treatment algorithm is rapidly evolving. For decades, chemotherapy has been the standard of care for ovarian cancer; however, treatment is changing to a targeted approach with…

MARKET OUTLOOK Chemotherapy has remained the standard of care for the treatment of ovarian cancer, but new classes of drugs such as angiogenesis inhibitors and, more recently, PARP inhibitors,…

KEY BENEFITS AND USES Pinpoint current drug positioning and uptake in one snapshot to facilitate forecasting. Drill down into physicians’ treatment sequences and understand who the…

Platinum-based chemotherapy has remained the standard of care for the treatment of platinum-sensitive ovarian cancer, but new classes of drugs such as angiogenesis inhibitors and more recently…

In recent years therapeutic options for ovarian cancer have increased. Prior to 2016, the only targeted therapy approved for the indication was AstraZeneca’s Lynparza. However, the treatment…

Biomarker-driven prescribing in oncology is playing an increasingly important role in various diseases, from indications in which its use is well entranced such as non-small-cell lung cancer (NSCLC…